Since there are very few treatment methods focused on managing<unk> , future research is targeted at inhibiting mutation of the pathway. However, this next step could be met with several complications as understanding the underlying mechanism of the mutation is a difficult task. The genetic coding that initiates a single mutation is sporadic and patterns are hard to detect in many cases. Even though very little research has been done to create inhibitors of the PI3K-AKT pathway, several pharmaceutical companies have begun to focus their interests in designing a prevention method for this purpose.
Megalencephaly
Schizencephaly
Hemihydranencephaly
Microhydranencephaly
Hydranencephaly
Holoprosencephaly
Lissencephaly
Microlissencephaly